Adverse Reactions and Benefits of Pharmacotherapy in Pediatric Chronic Pain

Overview

In a cohort of 142 pediatric patients with chronic non-cancer pain, 81% reported adverse effects within the first month of pharmacologic treatment, predominantly gastrointestinal and attention-related symptoms. Despite high rates of adverse effects, 77% of patients perceived benefits in pain relief, sleep, physical function, or mood, with benefits increasing alongside polypharmacy but decreasing per prescription.

Background

Chronic pain affects approximately 20% of children and adolescents, often leading to significant psychosocial and functional impairments. Pharmacological treatments are commonly used within interdisciplinary pain programs, yet pediatric-specific evidence on efficacy and safety remains limited. Many medications prescribed, such as gabapentinoids and antidepressants, lack formal pediatric approval and carry warnings for risks like suicidal ideation. Understanding the real-world risk–benefit profile of these therapies is critical for optimizing pediatric pain management.

Data Highlights

Key Findings

• Adverse effects were common within four weeks of starting pharmacotherapy, affecting 81% of pediatric patients.
• Gastrointestinal and attention-related adverse effects were the most frequently reported.
• Incidence of adverse effects increased with the number of concomitant medications, reaching 95% in patients on three or more drugs.
• Despite adverse effects, 77% of patients reported perceived benefits in at least one domain, primarily pain relief and improved sleep.
• The number of perceived benefit domains increased with polypharmacy, but benefits per individual prescription decreased as more medications were prescribed.

Clinical Implications

Clinicians should anticipate a high incidence of adverse effects early in pharmacologic treatment for pediatric chronic pain, especially when multiple medications are prescribed. Careful monitoring and open communication about both risks and perceived benefits are essential to optimize individualized treatment plans. These findings underscore the importance of balancing polypharmacy to maximize benefits while minimizing adverse effects in this vulnerable population.

Conclusion

Pharmacologic treatment in pediatric chronic non-cancer pain is associated with frequent adverse effects alongside meaningful patient-perceived benefits. These real-world data highlight the necessity for vigilant safety monitoring and shared decision-making to navigate the complex risk–benefit landscape.

References

1. Evaluating Adverse Reactions and Perceived Advantages of Pharmacotherapy in Pediatric Patients with Chronic Non-Cancer Pain